Evidence map›Paper›PMID 36598990›Full record

ArticleScience advances2023

Lactate metabolism is essential in early-onset mitochondrial myopathy.

Zhenkang Chen, Bogdan Bordieanu, Rushendhiran Kesavan, Nicholas P Lesner, Siva Sai Krishna Venigalla, Spencer D Shelton, Ralph J DeBerardinis, Prashant Mishra

Open access · goldAbstract read
In one paragraph

Article in Science advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Optimization ofMethods (San Diego, Calif.) · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Zhenkang ChenChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0002-7919-5546
Bogdan BordieanuChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0002-6356-7333
Rushendhiran KesavanChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0002-8540-8093
Nicholas P LesnerChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Siva Sai Krishna VenigallaChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0001-6795-2530
Spencer D SheltonChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0003-1236-5317
Ralph J DeBerardinisChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0002-2705-7432
Prashant MishraChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0003-2223-1742
Children's Medical Center · US

Funding

Metabolic Regulators of Tumor Growth and ProgressionR35CA220449 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI RALPH J DEBERARDINIS · 2017 to 2026
$9.4M
UT Southwestern NORCP30DK127984 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI Shawn C Burgess · 2022 to 2026
$7.4M
Engineering faithful animal models of mitochondrial diseaseDP2ES030449 · NIEHS · UT SOUTHWESTERN MEDICAL CENTER · PI MISHRA, PRASHANT · 2018 to 2018
$2.4M
Deciphering the role of amino acid transporters in mitochondrial myopathyR01AR073217 · NIAMS · UT SOUTHWESTERN MEDICAL CENTER · PI MISHRA, PRASHANT · 2018 to 2022
$1.8M
Examining Transsulfuration in Mitochondrial Hepatopathy in vivoF31DK122676 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI LESNER, NICHOLAS PAUL · 2020 to 2021
$49k
NCI NIH HHS R35 CA220449NIAMS NIH HHS R01 AR073217NIDDK NIH HHS F31 DK122676NIDDK NIH HHS P30 DK127984NIEHS NIH HHS DP2 ES030449
6 · The paper itself

Abstract

Myopathies secondary to mitochondrial electron transport chain (ETC) dysfunction can result in devastating disease. While the consequences of ETC defects have been extensively studied in culture, little in vivo data are available. Using a mouse model of severe, early-onset mitochondrial myopathy, we characterized the proteomic, transcriptomic, and metabolic characteristics of disease progression. Unexpectedly, ETC dysfunction in muscle results in reduced expression of glycolytic enzymes in our animal model and patient muscle biopsies. The decrease in glycolysis was mediated by loss of constitutive Hif1α signaling, down-regulation of the purine nucleotide cycle enzyme AMPD1, and activation of AMPK. In vivo isotope tracing experiments indicated that myopathic muscle relies on lactate import to supply central carbon metabolites. Inhibition of lactate import reduced steady-state levels of tricarboxylic acid cycle intermediates and compromised the life span of myopathic mice. These data indicate an unexpected mode of metabolic reprogramming in severe mitochondrial myopathy that regulates disease progression.

Identifiers

PMID36598990
PMCPMC9812384
OpenAlexW4313546067

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.